Diagnostic Center | October 03, 2023
Zydus announces IND clearance of a novel Anti-PCSK9 candidate
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
The companies will work with investigators to share the results with the scientific community
The campaign for the digital film is being amplified across various digital media platforms such as YouTube, Facebook, Instagram, Twitter, and LinkedIn
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Subscribe To Our Newsletter & Stay Updated
